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Introduction

Background
Urinary tract infections (UTIs) are among the most common bacterial infections both in the community and hospital setting. In the majority of cases, antibiotics are given empirically before the final bacteriology results are available. Therefore, area-specific monitoring studies to document the micro-organisms causing UTIs and their antimicrobial susceptibility is mandatory for helping the selection of an effective empirical treatment (Smith and Coast 2002 ). An increasing rate of antibiotic resistance among pathogens responsible for UTIs has caused growing concern worldwide (Kahlmeter and Menday 2003; Zhanel et al. 2006 ). Mechanisms of resistance against β-lactam antibiotics in gram-negative bacilli include production of TEM-and AmpC β-lactamases, porin deficiency and efflux mechanisms and, more recently, ExtendedSpectrum βlactamases (ESBL). Microorganisms responsible for UTIs such as E. coli and Klebsiella spp. remain the major ESBL-producing organisms isolated worldwide, but these enzymes have also been identified in several other members of the Enterobacteriaceae family and in certain non-fermenters (Jacoby and Munoz-Price 2005).
The aim of this prospective study was to obtain data on susceptibility patterns of pathogens responsible for both community and hospital UTIs in Rwanda to antimicrobial agents currently used to treat UTIs. In addition, for the first time, the prevalence and risk factors of ESBL-producing strains in Rwanda are described in this study.
Methodology
This study was conducted in both outpatients and inpatients with UTIs at University Teaching Hospital-Kigali and University teaching Hospital-Butare; two tertiary teaching hospitals after obtaining approval from the Research Ethics Committee of the Faculty of Medicine (FoMREC). The study was conducted in two parts. In the first part, between June and November 2009 a total of 1012 urine from patients received in the clinical microbiology laboratories of the two participating hospitals were analysed. For each patient, data were prospectively collected through a standardized questionnaire and their medical records were checked when necessary. Risk factors for ESBL positive were as follows: age, sex, presence of a urinary catheter; prior UTI, prior urinary catheter, hospitalization during the previous year; and antibiotic exposure during the preceding 6 months. Each specimen was cultured using a 0.001 ml calibrated loop to inoculate blood agar and MacConkey agar plates, incubated at 37°C for 18-24 hours and the number of colonies was counted. Significant bacteriuria was defined as greater than 10 5 colony forming units/ml of a single pathogen.
Antimicrobial susceptibility testing was performed using disk diffusion method according to the Clinical and Laboratory Standards Institute (CLSI) guidelines (CLI 2008) . Antibiotic disks were obtained from Oxoid (Oxoid ltd. England). Quality control was performed once weekly using test strains E. coli ATCC 25 922, Staphylococcus aureus ATCC 25923 and Pseudomonas aeruginosa ATCC 27853. Positive urine isolates obtained from the analysis were stored frozen at -80 0 C and selected for the second part of the study. In The second part of the study was done between February and August 2011, all stored isolates (196) were tested for ESBL production by the double disk synergy test (DDST) on MuellerHinton agar using ceftriaxone and ceftazidime placed at a distance of 15-20 mm apart from a disk containing amoxicillin plus clavulanic acid. A clear-cut extension of the inhibition zone around either ceftazidime or ceftriaxone disk towards the clavulanic acidcontaining disk (also called "ghost zone") was interpreted as positive for ESBL production (CLI 2008). Confirmed ESBLs were characterized by PCR amplification using primer sets for CTX-M, SHV, and TEM genes, followed by sequencing of the PCR products at the the laboratory of Ghent University, in Belgium.
Data processing and statistical analysis were performed using SPSS software version 16.0. Differences in group proportions for categorical variables were assessed using Chi-square or Fisher"s exact test. Logistic regression analysis was performed to identify risk factors ESBL production. A p value <0.05 was considered statistically significant.
Results
Of the 196 patients, 102 were outpatients and 94 were hospitalized patients. The mean age of the study population was 42 with a range of 18-90, and 71.9 % of the patients were female.
The distribution of uropathogens in outpatient and inpatients is shown in Table 1 . Escherichia coli was the most common uropathogen, accounting for infections in 119 (60.7%) of the 196 patients; and occurred significantly more frequently in urines from outpatients (70.6%) than from inpatients (50%). The proportion of Klebsiella sp., Proteus sp. and Citrobacter sp. was relatively higher in inpatients (24.5, 6.5, 7.4 and 6.4%) than in outpatients (13.7, 5.9, 2, and 1%). Pseudomonas aeruginosa was only isolated from inpatients (3.2%). Gram-positive microorganism grew in only 3.1% of the positive cultures, and were not further included in the study 
Discussion
The present study confirms that E. coli is still the most common uropathogen isolated from both in-and outpatients, but that various other bacteria cause infection, especially in inpatients ( We documented a remarkable high resistance to ciprofloxacin, which is of great concern because fluoroquinolones are the drugs of choice for first-line empiric treatment of both community and hospital acquired UTI in settings where resistance to trimethoprim/ sulfamethoxazole exceeds 20% and they have become more commonly prescribed as first-line antibiotic therapy in the last few years (Goettsch et al. 2000) . Resistance rates for ciprofloxacin against uncomplicated and complicated UTI strains were reported as 8.5% and 19.5% respectively by Alos and coworkers (Alos et al. 2006) . Recently, Arslan and co-workers reported 17% and 38% resistance rates for the uncomplicated and complicated UTI strains, respectively (Arslan et al. 2005) . Our rates were found to be much higher: 26.5% for the inpatient UTI strains, and 57.4% for the outpatient UTI strains.
Resistance rates in isolates of outpatients were also higher compared to studies from other countries for the majority of antimicrobials except third-generation cephalosporin ceftriaxime and ceftazidime. However, the resistance to third-generation cephalosporins was significantly higher in strains from inpatients ( Table 2 ). Randrianirina and coworkers have reported an increasing resistance rate to the third-generation cephalosporin in their study in patients aged 65 years (Randrianirina et al. 2007 ). The findings of the present study indicate that β -lactams, trimethoprim/sulfamethoxazole, nitrofurantoin and ciprofloxacin should no longer be used as empirical treatments of UTI in Rwanda, because of their high rate of resistance. Alternatives must be recommended, especially for empirical treatments of uncomplicated UTI (cystitis) in outpatients.
Fosfomycin-trometamol and imipinem were found to be the most effective antimicrobials, 99 and 93% E. coli isolates tested being susceptible respectively. As a result, fosfomycin-trometamol and imipinem may be the drugs of choice for empirical therapy of UTIs based on the in vitro data. Previous studies have reported fosfomycin-trometamol resistance rates of 0.3% in 288 and no resistance in 100 E. coli strains (Randrianirina et al. 2007 ). Schito in Pakistan have recorded 86.9 % of isolates being susceptible to imipinem (Schito 2003 (Akram et al. 2007 ) showed a higher percentage, than our study, of E. coli producing ESBL. The most common ESBLs identified among the isolates were members of the CTX-M15 with only one case of CTX-M14. Fig. 1 . CTX-M-type ESBLs, primarily CTX-M-15, have emerged as the predominant type of ESBL produced by common gram-negative rods in our health care system. Prior use of antibiotics, especially ciprofloxacin and thirdgeneration cephalosporins and in-hospital stay, both major risk factors retained in our multivariate analysis, were also found to be independent risk factors for ESBL positivity in previous studies 
Conclusion
Gram-negative organisms, especially E.coli were the most common organisms isolated. We found that antibiotics commonly used for the treatment of UTI in Rwanda such as nalidixic acid, nitrofurantoin and ciprofloxacin are far from effective. ESBL producers are, as in many countries, frequent in enterobacteriaceae in Rwanda. On the basis of our findings, we suggest that antimicrobial agent such as fosfomycin-trometamol could be alternative therapy for uncomplicated UTI, and should be introduced in the national guidelines.
